Key facts
- Okeiro’s last known valuation is $20.1M (Apr 2025).
- It has raised $12.3M; the latest was Early Stage VC ($10.9M) in Apr 2025.
- Notable investors include Alven Capital Partners, Inserm Transfert, BigBooster, Forepont Capital Partners, Red River West.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Okeiro
- ·The full record, as it builds
Funding rounds
No funding rounds for Okeiro are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Okeiro
Developer of a precision medicine platform designed to enable proactive monitoring and personalized care for transplant and chronic disease patients. The company's platform offers predictive algorithms, real-time data centralization, smart alerts, remote monitoring tools, digital twin simulations, integrated patient dashboards, automated risk scoring, and seamless communication channels with care teams, enabling healthcare professionals and life sciences organizations to anticipate clinical changes and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2023
- Employees
- 36
- Website
- okeiro.com/
- Ownership
- Privately Held (backing)
Okeiro doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Okeiro shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Okeiro in its N-PORT filings yet. We sweep new filings monthly.